Loading
Zhejiang Shengda Bio-Pharm Co., Ltd. Stock: price and insider trades · China
圣达生物
No insider purchase over the last 90 days. The latest, by 庞爱明, was filed 19 May 2021.
Zhejiang Shengda Bio-Pharm Co., Ltd.: what insiders have been doing
We have very little insider data for Zhejiang Shengda Bio-Pharm Co., Ltd. so far: the most recent filing dates from 19 May 2021. With so few records, no pattern can be drawn yet. These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
€3,528
1 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- -26.4%Entry CN¥17.26 · Close at T+365 CN¥12.71
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,256 of 23,476 companies
42.0
score / 100
Value38
Quality46
FCF yld-0.3%
Earn yld2.6%
EV/EBITDA17.4x
ROE3.3%
Gross mgn26%
Net mgn7.4%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥12.88
Analyst consensus
Income statement
RevenueCN¥844.5M
Gross profitCN¥220.9M26% margin
EBITDACN¥158.4M19% margin
Net incomeCN¥62.2M5.4% margin
Valuation
PER (trailing)53.7x
P/Book1.5x
Beta0.37
Balance sheet & cash
Market capCN¥2.4B
Total debtCN¥324.1M
Free Cash Flow-CN¥6.8M
Debt / Equity21%
Profitability & ownership
ROE3.3%
ROA1.6%
% insiders52.5%
% institutions2.5%
Last declaration on 19 May 2021
About Zhejiang Shengda Bio-Pharm Co., Ltd.
圣达生物 is a company focused on the agro-food sector, specializing in the research and development of biological products. It is listed on the XSHG market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations